What are the risk factors for adverse reactions to Plavix (clopidogrel) and Ubrelvy (ubrogepant)?

Risk Factors for Adverse Reactions to Plavix (Clopidogrel) and Ubrelvy (Ubrogepant)

Plavix (Clopidogrel) Risk Factors

Bleeding Risk Factors

The primary risk factors for bleeding with clopidogrel include advanced age (≥75 years), concomitant use of anticoagulants or other antiplatelets, history of gastrointestinal bleeding, and use of NSAIDs, SSRIs, or SNRIs. 1

• Age ≥75 years is an independent risk factor for increased gastrointestinal and intracranial bleeding 1
• Concomitant aspirin use increases major bleeding risk substantially (OR 2.83,95% CI 2.04-3.94) 2
• Long duration of therapy (>6 months) increases major bleeding risk (OR 1.74,95% CI 1.21-2.50) 2
• Active bleeding or history of GI bleeding represents the highest risk category and requires consideration of proton pump inhibitor co-therapy 1
• Concurrent use with anticoagulants, SSRIs, SNRIs, or corticosteroids significantly elevates bleeding risk 1, 3
• Peptic ulcer disease increases risk and warrants PPI prophylaxis 1

Reduced Efficacy Risk Factors

**CYP2C19 loss-of-function alleles (2, 3) are the most important genetic risk factors for clopidogrel treatment failure, resulting in reduced active metabolite formation and increased risk of major adverse cardiovascular events. 1, 4

• CYP2C19 poor metabolizers (two loss-of-function alleles) have significantly reduced clopidogrel effectiveness and should avoid clopidogrel entirely 1, 4
• CYP2C19 intermediate metabolizers (one loss-of-function allele) also have reduced effectiveness and alternative antiplatelet therapy should be considered 1, 4
• Concomitant use with proton pump inhibitors, particularly omeprazole, may reduce clopidogrel's antiplatelet effects through CYP2C19 inhibition 1
• Reduced renal function (both mild and severe) is a definite risk factor for clinical ineffectiveness 2
• Hypertension is associated with higher rates of clopidogrel resistance 5
• Elevated uric acid levels, higher mean platelet volume, and elevated platelet count correlate with clopidogrel resistance 5

Drug Interaction Risk Factors

• Strong CYP3A4 inhibitors can affect clopidogrel metabolism 1
• Moderate CYP3A4 inhibitors may reduce conversion to active metabolite 1
• Proton pump inhibitors (especially omeprazole) show the strongest evidence for interaction, though clinical significance remains debated 1

Other Clinical Risk Factors

• History of stroke or TIA is a contraindication for prasugrel but not clopidogrel; however, these patients may have altered risk-benefit profiles 1
• Body weight <60 kg increases exposure to active metabolites in some antiplatelet agents 1
• Gastrointestinal comorbidity increases risk of adverse drug reactions 6
• Non-compliance significantly impacts both efficacy and safety outcomes 6

---

Ubrelvy (Ubrogepant) Risk Factors

Hypersensitivity Reactions

Hypersensitivity reactions including anaphylaxis, dyspnea, facial or throat edema can occur within minutes to days after ubrogepant administration and require immediate discontinuation. 7

• History of serious hypersensitivity to ubrogepant is an absolute contraindication 7
• Reactions can manifest as anaphylaxis, dyspnea, facial/throat edema, rash, urticaria, or pruritus 7
• Most reactions occur within hours of dosing but can be delayed 7

Cardiovascular Risk Factors

New-onset hypertension or worsening of pre-existing hypertension can develop with CGRP antagonists like ubrogepant, most frequently within 7 days of therapy initiation. 7

• Pre-existing hypertension increases risk of blood pressure elevation requiring treatment or hospitalization 7
• Cardiovascular risk factors do not appear to increase treatment-emergent adverse events based on pooled trial data, though monitoring remains important 8
• Patients with major cardiovascular risk factors showed comparable safety profiles to those without such factors in phase 3 trials 8

Raynaud's Phenomenon Risk

Development or worsening of Raynaud's phenomenon can occur with ubrogepant, typically within 1.5 days of dosing, and may require discontinuation. 7

• History of Raynaud's phenomenon requires close monitoring for recurrence or worsening 7
• Serious outcomes including hospitalization and disability have been reported 7
• Discontinuation typically results in symptom resolution 7

Drug Interaction Risk Factors

• Strong CYP3A4 inhibitors are contraindicated with ubrogepant 7
• Moderate CYP3A4 inhibitors require dose reduction to 50 mg with avoidance of second dose within 24 hours 7
• Strong CYP3A4 inducers should be avoided as they reduce ubrogepant exposure 7
• BCRP and/or P-gp inhibitors require dose reduction to 50 mg 7

Hepatic and Renal Impairment

• Severe hepatic impairment (Child-Pugh Class C) requires dose reduction to 50 mg 7
• Severe renal impairment (CrCl 15-29 mL/min) requires dose reduction to 50 mg 7
• End-stage renal disease (CrCl <15 mL/min) warrants avoidance of ubrogepant 7

Common Adverse Events

• Fatigue occurs in approximately 27% of real-world patients 9
• Nausea is reported in clinical trials and real-world use 7, 9
• Somnolence is a common adverse reaction (≥2% and greater than placebo) 7
• Dry mouth affects approximately 7.5% of patients 9
• Adverse event rates in real-world settings (39.6%) are higher than in clinical trials 9

Concurrent CGRP Therapy

• Concurrent use with CGRP monoclonal antibodies does not increase overall adverse event rates but may increase moderate (versus mild) adverse events (47.8% vs 17.6%, p=0.048) 9